Targeting of NMDA receptors in new treatments for schizophrenia

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 9, 2014, Pages 1049-1063

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cystine glutamate antiporter; d serine; Glutamate; Glutathione; Glycine; Glycine transporter; Kynurenic acid; N acetylcysteine; NMDA receptor; Sulforaphane

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCYSTEINE; BENZOIC ACID; BITOPERTIN; CYCLOSERINE; D AMINO ACID OXIDASE INHIBITOR; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; ENZYME INHIBITOR; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCINE; GLYCINE HYDROXYMETHYLTRANSFERASE; GLYCINE TRANSPORTER 1; KYNURENIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PLACEBO; SARCOSINE; UNCLASSIFIED DRUG; ANTIOXIDANT; NEUROLEPTIC AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; ANIMAL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; GLUTATHIONE; HUMANS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84906228003     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.934225     Document Type: Review

References (152)

1. Sullivan PF. The genetics of schizophrenia. PLoS Med 2005;2:e212
2. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405-96
3. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8
4. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1995;3:241-53
5. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007
6. Krystal JH, D'Souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125-43
7. Hashimoto K, Okamura N, Shimizu E, et al. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem - CNS Agents 2004;4:147-54
8. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci 2006;4:3-10
9. Hashimoto K, Malchow B, Falkai P, et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263:367-77
10. Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011;3:102mr2
11. Moghaddam B, Javitt D. From revolution to evolution: the gluatamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15
12. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull 2012;38:920-6
13. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
14. Weickert CS, Fung SJ, Catts VS, et al. Molecular evidence of N-methyl-Daspartate receptor hypofunction in schizophrenia. Mol Psychiatry 2013;18:1185-92
15. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003;361:417-19
16. Schwartz TL, Sachdeva S, Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr Pharm Des 2012;18:1580-92
17. Kim JS, Kornhuber HH, Holzmüller B, et al. Reduction of cerebrospinal fluid glutamic acid in Huntigton's chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 1980;228:7-10
18. Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982;231:221-5
19. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982;28:81-5
20. Hashimoto K, Engberg G, Shimizu E, et al. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005;5:6
21. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005;1:151-63
22. Hashimoto K. Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain. Schizophr Res 2014;156:281-2
23. Shirayama Y, Obata T, Matsuzawa D, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010;49:2783-90
24. Bustillo JR, Chen H, Jones T, et al. Increased glutamine in patients undergoing long-term treatment for schizophrenia. A proton magnetic resonance spectroscopy study at 3T. JAMA Psychiatry 2014;71:265-72
25. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-16
26. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004;174:32-8
27. Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004;66:89-96
28. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia. A critical review and meta-analysis. Curr Pharm Des 2010;16:522-37
29. Maekawa M, Ohnishi T, Hashimoto K, et al. Analysis of strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia. J Neurochem 2010;115:1374-85
30. Abarinov EV, Beaudin AE, Field MS, et al. Disruption of shmt1 imapirs hippocampus neurogenesis and mnemonic function in mice. J Nutr 2013;143:1028-35
31. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225-34
32. Horio M, Mori H, Hashimoto K. Is Dcycloserine a prodrug for D-serine in the brain? Biol Psychiatry 2013;73:e33-4
33. Wolosker H. Serine racemase and the serine shuttle between neurons and astrocytes. Biochem Biophys Acta 2011;1814:1558-66
34. Inoue R, Hashimoto K, Mori H. NMDA- and beta-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J Neurosci 2008;28:14486-91
35. Horio M, Kohno M, Fujita Y, et al. Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem Int 2011;59:853-9
36. Horio M, Kohno M, Fujita Y, et al. Role of serine racemase in behavioral sensitization in mice after repeated administration of methamphetamine. PLoS One 2012;7:e35494
37. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the NMDA receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2013;60:572-6
38. Yamada K, Ohnishi T, Hashimoto K, et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005;57:1493-503
39. Hashimoto K, Engberg G, Shimizu E, et al. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:767-9
40. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007;90:41-51
41. Calcia MA, Madeira C, Alheira FV, et al. Plasma levels of D-serine in Brazillian individuals with schizophrenia. Schizophr Res 2012;142:83-7
42. Lin CH, Chang HT, Chen YJ, et al. Distinctively higher plasma G72 protein levels in patients with schizophrenia than in the healthy individuals. Mol Psychiatry 2014;19:636-7
43. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for Damino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002;99:13675-80
44. Shinkai T, De Luca V, Hwang R, et al. Association analyses of the DAOA/ G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromolecular Med 2007;9:169-77
45. Verrall L, Burnet PW, Betts JF, et al. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry 2010;15:122-37
46. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-9
47. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005;57:577-85
48. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebocontrolled study. Arch Gen Psychiatry 2005;62:1196-204
49. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010;121:125-30
50. Javitt DC, Zukin SR, Heresco-levy U, et al. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 2012;38:958-66
51. Ferraris D, Duvall B, Ko YS, et al. Synthesis and biological evaluation of Damino acid oxidase inhibitors. J Med Chem 2008;51:3357-9
52. Hashimoto K, Fujita Y, Horio M, et al. Co-administration of D-amino acid oxidase inhibitor potentiates the efficacy of D-serine on prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009;65:1103-6
53. Ferraris DV, Tsukamoto T. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des 2011;17:103-11
54. Sacchi S, Rosini E, Pollegioni L, et al. D-amino acid oxidase inhibitors as a novel class of drugs for schizophgrenia therapy. Curr Pharm Des 2013;19:2499-511
55. Hagiwara H, Iyo M, Hashimoto K. Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by D-serine. PLoS One 2013;8:e62438
56. Javitt DC. Glutamatergic based early intervention in schizophrenia. In the symposium "Schizophrenia: could it be prevented?" A Satellite Meeting of the 2014 Annual Meeting of The Society of Biological Psychiatry; 7 May 2014; New York, USA
57. Hashimoto K. Food coloring, sodium benzoate preservative and D-serine: implication for behavior. In: Preedy VR, editor. The handbook of behavior, diet and nutrition. Springer Publishers, New York; 2011. p. 577-84
58. Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, doubleblind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013;70:1267-75
59. Hashimoto K. Comments on "The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia". J Psychopharmacol 2010;24:1133-4
60. Jana A, Modi KK, Roy A, et al. Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders. J Neuroimmune Pharmacol 2013;8:739-55
61. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004;45:104-14
62. Hashimoto K. BDNF variant linked to anxiety-related behaviors. Bioessays 2007;29:116-19
63. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 2013;100:15-29
64. Hashimoto K. Glycine transportor-1: a potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:112-20
65. Hashimoto K, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008;18:414-21
66. Karasawa J, Hashimoto K, Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008;186:78-83
67. Javitt DC. Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 2012;213:367-99
68. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-6
69. Lane HY, Huang CL, Wu PL, et al. Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006;60:645-9
70. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008;63:9-12
71. Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebocontrolled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010;13:451-60
72. Mortensen PB. The incidence of cancer in schizophrenic patients. J Epidemiol Community Health 1989;43:43-7
73. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-14
74. Hashimoto K. Sarcosine and decreased risk for prostate cancer in schizophrenia. Open Clin Chem J 2009;2:22-3
75. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4- (3-fluoro-5-trifluoromethylpyridin-2- yl) piperazin-1-yl][5- methanesulfonyl-2-((S)- 2,2,2-trifluoro-1-methylethoxy)phenyl] methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010;53:4603-14
76. Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012;62:1152-61
77. Martin-Facklam M, Pizzagalli F, Zhou Y, et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology 2013;38:504-12
78. Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia. A randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71:637-46
79. Roche Media Release (January 21, 2014): roche provides update on the first two of six phase III studies of bitopertin in schizophrenia. 2014. Available from: http://www. roche. com/media/ media-releases/med-cor-2014-01-21. htm
80. Bugarski-Kirola D. Efficacy and safety of adjunctive bitopertin versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotic - Update from the serachlyte programme. The 4th Schizophrenia International Resaerch Society Conference; 06 April 2014; Florence, Italy
81. Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur Neuropsychopharmacol 2014;27:1024-36
82. Goff DC. Bitopertin. The good news and bad news. JAMA Psychiatry 2014;71:621-2
83. Schwarcz R, Bruno JP, Muchowski PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-77
84. Hashimoto K, Koike K, Shimizu E, et al. alpha7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem CNS Agents 2005;5:171-84
85. Toyohara J, Hashimoto K. alpha7 Nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J 2010;4:37-56
86. Hashimoto K. Targeting of alpha7 nicotinic acetylcholine receptor in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pham Des In press
87. Erhardt S, Blennow K, Nordin C, et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schziophrenia. Neurosci Lett 2001;313:96-8
88. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005;80:315-22
89. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-30
90. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011;37:1147-56
91. Miller CL, Llenos IC, Dulay JR, et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006;1073-1074:25-37
92. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3- monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011;68:665-74
93. Alexander KS, Wu HQ, Schwarcz R, et al. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 2012;220:627-37
94. Alexander KS, Pocivavsek A, Wu HQ, et al. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 2013;238:19-28
95. Pocivavsek A, Thomas MA, Elmer GI, et al. Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl) 2014;Epub ahead of print
96. Müller N, Myint AM, Schwarz MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011;17:130-6
97. Aschner M. Neuron-astrocyte interactions: implications for cellular energetics and antioxidant levels. Neurotoxicology 2000;21:1101-7
98. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000;62:649-71
99. Kohr G, Eckardt S, Luddens H, et al. NMDA receptor channels: subunitspecific potentiation by reducing agents. Neuron 1994;12:1031-40
100. Sullivan JM, Traynelis SF, Chen HS, et al. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. Neuron 1994;13:929-36
101. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-8
102. Terpstra M, Vaughan TJ, Ugurbil K, et al. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA 2005;18:276-82
103. Matsuzawa D, Obata T, Shirayama Y, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008;3:e1944
104. Wood SJ, Berger GE, Wellard RM, et al. Medial temporal lobe glutathjione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009;33:354-7
105. Raffa M, Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1178-83
106. Tosic M, Ott J, Barral S, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006;79:586-92
107. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007;104:16621-6
108. Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 2011;15:2057-65
109. Kulak A, Steullet P, Cabungcal JH, et al. Redox dysregulation in the pathophysiology of schziophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal 2013;18:1428-43
110. Poels EMP, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014;19:20-9
111. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry 2014;27:185-90
112. Berk M, Malhi GS, Gray LJ, et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167-77
113. Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system x (c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013;18:522-55
114. Fukami G, Hashimoto K, Koike K, et al. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 2004;1016:90-5
115. Hashimoto K, Tsukada H, Nishiyama S, et al. Protective effects of N-acetyl-Lcysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 2004;29:2018-23
116. Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008;33:1760-72
117. Steullet P, Cabungcal JH, Kulak A, et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010;30:2547-58
118. das Neves Duarte JM, Kulak A, Gholam-Razaee MM, et al. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry 2012;71:1006-14
119. Cabungcal JH, Steullet P, Kraftsik R, et al. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry 2013;73:574-82
120. Herrmann AP, Benvenutti R, Pilz LK, et al. N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice. Schizophr Res 2014;155:109-11
121. Asevedo E, Cunha GR, Zugman A, et al. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Rev Neurosci 2012;23:353-62
122. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a doubleblind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361-8
123. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negatiovity in schziophrenia patients. Neuropsychopharmacology 2008;33:2187-99
124. Gunduz-Bruce H, Reinhart RM, Roach BJ, et al. Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry 2012;71:969-77
125. Carmeli C, Knyazeva MG, Cuenod M, et al. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebnocontrolled trial. PLoS One 2012;7:e29341
126. Farokhnia M, Azarkolah A, Adinehfar F, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, doubleblind, placebo-controlled study. Clin Neuropharmacol 2013;36:185-92
127. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of antiinflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014;40:181-91
128. Miyake N, Miyamoto S, Yamashita Y, et al. Effects of N-acetylcysteine in subjects with at-risk mental health (in Japanese). The 9th Annual Meeting of Japanese Society of Schizophrenia Research; 14 March 2014; Kyoto, Japan
129. Hashimoto K. Regarding "Nacetylcysteine as a glutathione precursor for schizophrenia - a double blind, randomized, placebo-controlled trial". Biol Psychiatry 2008;64:e1
130. Giustarini D, Milzani A, Dalle-Donne I, et al. N-Acetylcysteine ethyl ester (NACET): a novel lipophilic cellpermeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochem Pharmacol 2012;84:1522-33
131. Sunitha K, Hemshekhar M, Thushara RM, et al. N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine. Free Radic Res 2013;47:357-67
132. Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008;7:68-83
133. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatrry Clin Neurosci 2010;64:341-57
134. Weickert CS, Weickert TW, Pillai A, et al. Biomarkers in schizophrenia: a brief conceptional consideration. Dis Markers 2013;35:3-9
135. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 2014;42:93-115
136. Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev 2014;45:134-41
137. Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 2013;150:434-41
138. Kinon B. The development of pomaglumetad methionil as a glutamatebased pharmacotherapy for schizophrenia: lesson learned. The 4th Schizophrenia International Resaerch Society Conference; 08 April 2014; Florence, Italy
139. Lilly Media Release (August 29, 2012): lilly stops phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results. 2012. Available from: https://investor. lilly. com/releasedetail. cfm? ReleaseID=703018
140. NIMH Resaerch Domain Criteria (RDoC). 2011. Available from: http://www. nimh. nih. gov/researchpriorities/ rdoc/index. shtml. Draft 3. 1
141. Solis M. Outlook Schizophrenia. Prevention. Before the break. Nature 2014;508:S12-13
142. McGrath JJ, Burne TH, Féron F, et al. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull 2010;36:1073-8
143. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54
144. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012;69:562-71
145. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009;9:197-204
146. Hashimoto K. Can sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets 2009;8:470-4
147. Ishikawa M, Hashimoto K. Alpha7 nicotinic receptor: a potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:121-9
148. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr Pharm Des 2012;18:875-83
149. Yoshida T, Iyo M, Hashimoto K. Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia. Curr Psychiatry Rev 2012;8:140-50
150. Chen H, Wu J, Zhang J, et al. Protective effects of antioxidant sulforaphane on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berl) 2012;222:37-45
151. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Clin Psychopharmacol Neurosci 2012;10:94-8
152. Hashimoto K. Sulforaphane as a potential therapeutic compound for schizophrenia. In the symposium "From pathway to pharmaceuticals: emerging oxidative stress and neuroprotective mechanisms in neuropsychiatric disorders". The 69th Annual Scientific Meeting of Society of Biological Psychiatry; 10 May 2014; New York, USA